Abbott Laboratories Surges to 51st in Trading Volume with $1.128 Billion Day

Abbott Laboratories reported a trading volume of $1.128 billion on June 24, 2025, marking a 73.58% increase from the previous day. This volume placed Abbott in the 51st position among all stocks traded that day. The company's stock price has been on an upward trajectory, rising 3.62% and marking its fourth consecutive day of gains, with a total increase of 4.38% over the past four days.

Abbott Laboratories has announced that it will be hosting a conference call to discuss its second-quarter financial results. The call is scheduled for July 20, 2025, at 8:30 AM Eastern Time. During the call, the company's management team will provide an overview of the financial performance for the quarter and discuss the company's strategic initiatives and outlook for the remainder of the year.

Abbott Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its new FreeStyle Libre 3 system. This system is designed to provide continuous glucose monitoring for people with diabetes, offering real-time glucose readings and alerts. The approval is expected to boost Abbott's diabetes care segment, which has been a key driver of the company's growth in recent years.

Abbott Laboratories has entered into a strategic partnership with a leading healthcare provider to expand the distribution of its medical devices. This partnership aims to enhance the availability of Abbott's innovative medical technologies, including its cardiac and vascular devices, to a broader patient population. The collaboration is expected to drive revenue growth and strengthen Abbott's market position in the medical device sector.